The cost-effectiveness of metformin in pre-diabetics: a systematic literature review of health economic evaluations

Cost saving analysis of prediabetes intervention modalities in comparison with inaction using Markov state transition model—A multiregional case study

“…Although there is no universally accepted T2D prediction model, individuals aged ≥25 y with BMI ≥24 and impaired plasma glucose are considered high risk. 5 People with prediabetes incur direct medical costs related to glucose testing, increased medical visits, and care associated with early diabetes-related risk management. A US study found that, annually, people with prediabetes incur 1.8 times the average number of ambulatory visits for endocrine complications and 1.5 times the average number for hypertension.…”

“…Additionally, for those who cannot practically comply with ILC due to cost constraints or inability to adhere to ILC, metformin was considered an economically feasible option. 5 Furthermore, a 2017 review of 27 studies in the United Kingdom explored the cost-effectiveness of lifestyle interventions and metformin in reducing the subsequent incidence of T2D. The study found that metformin and lifestyle programs appear equally cost effective when only the costs of the health system are taken into account, but metformin is more cost effective when costs of participants' time (participating in and traveling to program activities) are included.…”

“…Parameters such as age, gender, ethnicity, body mass index (BMI), and a family history of diabetes are risk factors for developing T2D. Although there is no universally accepted T2D prediction model, individuals aged ≥25 y with BMI ≥24 and impaired plasma glucose are considered high risk 5 …”

“…The study found that ILC is cost effective vs metformin, but metformin may result in cost savings due to the high costs of implementing and maintaining an ILC program. Additionally, for those who cannot practically comply with ILC due to cost constraints or inability to adhere to ILC, metformin was considered an economically feasible option 5 . Furthermore, a 2017 review of 27 studies in the United Kingdom explored the cost‐effectiveness of lifestyle interventions and metformin in reducing the subsequent incidence of T2D.…”

A Technical Review of the ISPOR Presentations Database Identified Issues in the Search Interface and Areas for Future Development

“…Although the presentations focus on health economics and outcomes research, the topics presented by researchers can be broad in scope. This makes the ISPOR presentations database a recommended resource for researchers interested in health technology assessment and a valuable resource for researchers looking for economic, cost, or outcomes data across a range of health topics (2;3).…”